Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives.
Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives.
复制标题
DOI：
10.3390/cancers12092362
复制
发表时间：
2020-08-21
期刊：
影响因子：
5.2
通讯作者：
Enrico D
中科院分区：
文献类型：
--
作者：
Chacón M;Pfluger Y;Angel M;Waisberg F;Enrico D
恶性黑色素瘤是最具侵袭性的皮肤癌类型。现代疗法，包括靶向药物和免疫检查点抑制剂，已经改变了这种疾病的令人沮丧的预后。然而，大多数证据是通过研究皮肤黑色素瘤（CM）的常见亚型患者获得的。因此，有一个新兴的需要，以了解不寻常的黑色素瘤亚型的分子基础和治疗方法。即使是罕见或罕见的黑色素瘤的标准化定义也没有明确建立。出于这个原因，我们回顾了这个具有挑战性的主题，考虑临床和分子的角度，包括不常见的CM-不与经典的V600 E/K BRAF突变-恶性粘膜和葡萄膜黑色素瘤，和一些不寻常的独立实体，如无色素，促纤维增生，或斯皮茨样黑色素瘤。最后，我们收集了关于非传统原发部位黑色素瘤的信息，这些原发部位如脑膜、真皮、淋巴结、食管和乳房等独特部位。这篇综述的目的是总结和强调关于罕见黑色素瘤的主要科学证据，特别关注治疗前景。
Malignant melanoma represents the most aggressive type of skin cancer. Modern therapies, including targeted agents and immune checkpoint inhibitors, have changed the dismal prognosis that characterized this disease. However, most evidence was obtained by studying patients with frequent subtypes of cutaneous melanoma (CM). Consequently, there is an emerging need to understand the molecular basis and treatment approaches for unusual melanoma subtypes. Even a standardized definition of infrequent or rare melanoma is not clearly established. For that reason, we reviewed this challenging topic considering clinical and molecular perspectives, including uncommon CMs—not associated with classical V600E/K BRAF mutations—malignant mucosal and uveal melanomas, and some unusual independent entities, such as amelanotic, desmoplastic, or spitzoid melanomas. Finally, we collected information regarding melanomas from non-traditional primary sites, which emerge from locations as unique as meninges, dermis, lymph nodes, the esophagus, and breasts. The aim of this review is to summarize and highlight the main scientific evidence regarding rare melanomas, with a particular focus on treatment perspectives.
登录
查看更多内容
影响因子：
3
作者：
Bai, X.;Mao, L. L.;Si, L.
通讯作者：
Si, L.
影响因子：
51.1
作者：
Ascierto, Paolo A.;Schadendorf, Dirk;Dummer, Reinhard
通讯作者：
Dummer, Reinhard
DOI：
10.1097/pas.0000000000000611
发表时间：
2016-06
期刊：
The American journal of surgical pathology
影响因子：
--
作者：
Busam KJ;Vilain RE;Lum T;Busam JA;Hollmann TJ;Saw RP;Coit DC;Scolyer RA;Wiesner T
通讯作者：
Wiesner T
影响因子：
3.7
作者：
Basile, Maria Sofia;Mazzon, Emanuela;Reibaldi, Michele
通讯作者：
Reibaldi, Michele
用Trametinib和GSK2141795抑制双MEK/AKT抑制，在转移性NRAS突变和野生型黑色素瘤中不会产生临床益处。
影响因子：
4.3
作者：
Algazi AP;Esteve-Puig R;Nosrati A;Hinds B;Hobbs-Muthukumar A;Nandoskar P;Ortiz-Urda S;Chapman PB;Daud A
通讯作者：
Daud A